LXRX
Price
$1.97
Change
-$0.06 (-2.96%)
Updated
Apr 12, 6:59 PM EST
19 days until earnings call
SAVA
Price
$22.75
Change
-$3.36 (-12.87%)
Updated
Apr 12, 6:59 PM EST
16 days until earnings call
Ad is loading...

Compare predictions LXRX vs SAVA

Header iconLXRX vs SAVA Comparison
Open Charts LXRX vs SAVABanner chart's image
Lexicon Pharmaceuticals
Price$1.97
Change-$0.06 (-2.96%)
Volume$1.26M
CapitalizationN/A
Cassava Sciences
Price$22.75
Change-$3.36 (-12.87%)
Volume$1.08M
CapitalizationN/A
View a ticker or compare two or three
LXRX vs SAVA Comparison Chart

Loading...

LXRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SAVADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
LXRX vs. SAVA commentary
Apr 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a Hold and SAVA is a Buy.

COMPARISON
Comparison
Apr 14, 2024
Stock price -- (LXRX: $2.29 vs. SAVA: $20.29)
Brand notoriety: LXRX and SAVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 30% vs. SAVA: 75%
Market capitalization -- LXRX: $562.65M vs. SAVA: $877.46M
LXRX [@Biotechnology] is valued at $562.65M. SAVA’s [@Biotechnology] market capitalization is $877.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $568.84B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whileSAVA’s FA Score has 0 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • SAVA’s FA Score: 0 green, 5 red.
According to our system of comparison, LXRX is a better buy in the long-term than SAVA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 2 TA indicator(s) are bullish while SAVA’s TA Score has 5 bullish TA indicator(s).

  • LXRX’s TA Score: 2 bullish, 6 bearish.
  • SAVA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SAVA is a better buy in the short-term than LXRX.

Price Growth

LXRX (@Biotechnology) experienced а +7.78% price change this week, while SAVA (@Biotechnology) price change was +2.99% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.71%. For the same industry, the average monthly price growth was +6.49%, and the average quarterly price growth was +103.81%.

Reported Earning Dates

LXRX is expected to report earnings on May 02, 2024.

SAVA is expected to report earnings on Apr 29, 2024.

Industries' Descriptions

@Biotechnology (+4.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for LXRX with price predictions.
OPEN
A.I.dvisor published
a Summary for SAVA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SAVA($877M) has a higher market cap than LXRX($563M). LXRX YTD gains are higher at: 49.346 vs. SAVA (-9.862). SAVA has higher annual earnings (EBITDA): -104.43M vs. LXRX (-163.46M). LXRX has more cash in the bank: 170M vs. SAVA (121M). SAVA has less debt than LXRX: SAVA (0) vs LXRX (106M). LXRX has higher revenues than SAVA: LXRX (1.2M) vs SAVA (0).
LXRXSAVALXRX / SAVA
Capitalization563M877M64%
EBITDA-163.46M-104.43M157%
Gain YTD49.346-9.862-500%
P/E Ratio12.27N/A-
Revenue1.2M0-
Total Cash170M121M140%
Total Debt106M0-
FUNDAMENTALS RATINGS
LXRX vs SAVA: Fundamental Ratings
LXRX
SAVA
OUTLOOK RATING
1..100
674
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
3863
P/E GROWTH RATING
1..100
30100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAVA's Valuation (55) in the Pharmaceuticals Other industry is in the same range as LXRX (79) in the Biotechnology industry. This means that SAVA’s stock grew similarly to LXRX’s over the last 12 months.

SAVA's Profit vs Risk Rating (79) in the Pharmaceuticals Other industry is in the same range as LXRX (100) in the Biotechnology industry. This means that SAVA’s stock grew similarly to LXRX’s over the last 12 months.

SAVA's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as LXRX (99) in the Biotechnology industry. This means that SAVA’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (38) in the Biotechnology industry is in the same range as SAVA (63) in the Pharmaceuticals Other industry. This means that LXRX’s stock grew similarly to SAVA’s over the last 12 months.

LXRX's P/E Growth Rating (30) in the Biotechnology industry is significantly better than the same rating for SAVA (100) in the Pharmaceuticals Other industry. This means that LXRX’s stock grew significantly faster than SAVA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXSAVA
RSI
ODDS (%)
N/A
Bullish Trend 13 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 13 days ago
81%
Bullish Trend 13 days ago
90%
Momentum
ODDS (%)
Bearish Trend 13 days ago
82%
Bearish Trend 13 days ago
85%
MACD
ODDS (%)
N/A
Bullish Trend 13 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 13 days ago
81%
Bullish Trend 13 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 13 days ago
88%
Bearish Trend 13 days ago
89%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 18 days ago
84%
Declines
ODDS (%)
Bearish Trend 19 days ago
85%
Bearish Trend 20 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 13 days ago
90%
Bullish Trend 13 days ago
90%
Aroon
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 13 days ago
86%
View a ticker or compare two or three
Ad is loading...
LXRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SAVADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SLFYX7.82N/A
N/A
SEI Multi-Asset Inflation Mgd Y (SIMT)
FICVX33.30-0.07
-0.21%
Fidelity Advisor Convertible Secs I
CIAGX11.05-0.03
-0.27%
AB Concentrated International Growth A
VIOAX9.62-0.04
-0.41%
VELA Income Opportunities A
BBGSX15.66-0.10
-0.63%
Bridge Builder Small/Mid Cap Growth

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
N/A
CRSP - SAVA
35%
Loosely correlated
+0.03%
IBRX - SAVA
29%
Poorly correlated
-0.74%
ATXI - SAVA
27%
Poorly correlated
+1.76%
LXRX - SAVA
26%
Poorly correlated
-4.79%
AMRN - SAVA
26%
Poorly correlated
-0.99%
More